Great Lakes Advisors LLC Sells 5,801 Shares of RxSight, Inc. (NASDAQ:RXST)

Great Lakes Advisors LLC decreased its holdings in RxSight, Inc. (NASDAQ:RXST) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 179,345 shares of the company’s stock after selling 5,801 shares during the period. Great Lakes Advisors LLC owned about 0.45% of RxSight worth $6,166,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of RXST. Brown Capital Management LLC purchased a new stake in shares of RxSight during the third quarter valued at $26,813,000. Point72 Asset Management L.P. boosted its holdings in shares of RxSight by 610.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock valued at $22,094,000 after acquiring an additional 384,041 shares during the last quarter. Thrivent Financial for Lutherans bought a new stake in shares of RxSight in the third quarter worth approximately $11,350,000. RA Capital Management L.P. raised its holdings in shares of RxSight by 6.0% during the third quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock valued at $193,609,000 after purchasing an additional 222,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in RxSight by 17.7% during the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock valued at $40,398,000 after purchasing an additional 122,775 shares during the period. Hedge funds and other institutional investors own 78.78% of the company’s stock.

RxSight Stock Down 3.3 %

NASDAQ RXST opened at $25.22 on Friday. RxSight, Inc. has a 52 week low of $24.64 and a 52 week high of $66.54. The company has a market capitalization of $1.02 billion, a P/E ratio of -30.39 and a beta of 1.22. The stock’s 50-day moving average price is $30.76 and its 200-day moving average price is $41.40.

RxSight (NASDAQ:RXST) last released its earnings results on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). The firm had revenue of $40.21 million for the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. Research analysts anticipate that RxSight, Inc. will post -0.7 EPS for the current year.

Insider Activity

In other RxSight news, Director Shweta Maniar sold 3,519 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total value of $108,631.53. Following the completion of the transaction, the director now directly owns 7,383 shares in the company, valued at $227,913.21. This represents a 32.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jesse Anderson Corley acquired 1,443 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were bought at an average cost of $31.18 per share, with a total value of $44,992.74. Following the completion of the acquisition, the director now owns 1,443 shares in the company, valued at approximately $44,992.74. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 9.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. UBS Group initiated coverage on shares of RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 target price for the company. Stifel Nicolaus reduced their price objective on RxSight from $35.00 to $33.00 and set a “hold” rating for the company in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $43.00 target price on shares of RxSight in a report on Wednesday, February 26th. JPMorgan Chase & Co. dropped their target price on RxSight from $62.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company reduced their price target on shares of RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, RxSight currently has an average rating of “Moderate Buy” and a consensus target price of $51.63.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.